Loading
Protein Degradation and Inhibitors / HER2/EGFR in Cancer Research / Chromatin Remodeling and Cancer · Journal article
Theoretical and Natural Science · September 8, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing that local delivery of LZK-PROTAC via dissolving microneedles could target both kinase-dependent and non-kinase functions of LZK in oral squamous cell carcinoma as a postoperative adjuvant. The proposal is mechanistically motivated but remains theoretical, with no preclinical or clinical evidence presented in the source text.
Journal article. Patients with stage I–II oral squamous cell carcinoma (proposed target).
LZK maintains c-MYC stability and stabilizes gain-of-function mutant p53, both implicated in OSCC pathogenesis PROTAC-mediated LZK degradation could block both catalytic and non-catalytic functions Dissolving microneedles may enable local delivery and reduce systemic exposure compared to systemic PROTAC delivery
No efficacy, safety, or pharmacokinetic data for LZK-PROTAC or dissolving microneedles in any model
This review identifies a potential postoperative adjuvant strategy but provides no evidence to guide clinical decision-making. Preclinical and clinical trials would be required before any recommendation could be made.
This is a narrative review proposing a theoretical therapeutic strategy combining LZK-PROTAC degradation with dissolving microneedle delivery for OSCC; no clinical trial data, preclinical evidence, or mechanistic validation is presented.
This review identifies a potential postoperative adjuvant strategy but provides no evidence to guide clinical decision-making. Preclinical and clinical trials would be required before any recommendation could be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Oral squamous cell carcinoma (OSCC) is the predominant histological type of oral cancer, with a continuously increasing disease burden and unsatisfactory long-term survival. c-MYC and gain-of-function mutant p53 (GOF-p53) are important oncogenic factors in OSCC/head and neck squamous cell carcinoma (HNSCC), but both remain difficult to target directly. Leucine zipper-bearing kinase (LZK) can maintain c-MYC stability through kinase-dependent mechanisms and stabilize GOF-p53 through non-kinase-dependent scaffold functions. Proteolysis-targeting chimera (PROTAC)-mediated degradation of LZK may simultaneously block its catalytic and non-catalytic functions; however, this strategy is limited by the large molecular size, poor membrane permeability, and restricted systemic delivery of PROTAC molecules. Dissolving microneedles (DMNs) may enable local delivery and reduce systemic exposure. This review summarizes recent advances in LZK-PROTAC and dissolving microneedle-mediated delivery, and discusses their potential value as postoperative adjuvant therapy for stage I-II OSCC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.